Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

6. keynote david dodd vaxy gen, geovax

961 views

Published on

Published in: Health & Medicine
  • Be the first to comment

6. keynote david dodd vaxy gen, geovax

  1. 1. GeoVax Labs, Inc. October 14, 2011 Greater Rome Chamber of Commerce 2011 Technology Symposium O11_IRG
  2. 2. <ul><li>Comments made today contain forward looking </li></ul><ul><li>statements as described under the Private Securities </li></ul><ul><li>Litigation Reform Act of 1995. Our forward looking </li></ul><ul><li>statements represent our current view and are subject to </li></ul><ul><li>risks and uncertainties. These risks include the risk that </li></ul><ul><li>we may not be able to obtain needed funding, that the </li></ul><ul><li>products we have under development may not prove </li></ul><ul><li>successful, and other risks including those set forth </li></ul><ul><li>under “risk factors” in our Form 10-K and our other </li></ul><ul><li>SEC filings. </li></ul>Disclaimer
  3. 3. SOURCE: 2009 Report on the Global AIDS Epidemic, UNAIDS/WHO (December 2009) Total Living with HIV: 33.4M Total Clade B: 3.5M New Infections: 2.7M New Clade B:185,400 HIV/AIDS – A Continuing Global Challenge O11_IRG / North America 1.4 M 55,000 NEW Caribbean 240,000 20,000 NEW Latin America Clade B 900,000 76,500 NEW Western/Central Europe 850,000 30,000 NEW Middle East / North Africa 310,000 35,000 NEW Sub-Saharan Africa 22.4M 1.9 M NEW Eastern Europe/ Central Asia 1.5 M 110,000 NEW South/Southeast Asia 3.8 M 280,000 NEW Oceania 59,000 3,900 NEW East Asia 850,000 75,000 NEW Latin America Other 900,000 93,500 NEW B B B B C C C
  4. 4. SOURCE: CDC Fact Sheet – Estimates of New HIV Infections in the United States (August 2008) Current Rate of New Infection:55,000-58,000 per year * Estimated Cost for Each U.S. Infection = $500,000 (Aggregate, $27.5 billion/year) * AIDS 2010 Annual Meeting (Atlanta GA) Estimates for New HIV Infections in US O11_IRG / 0 1979 1983 1987 1989 1993 1997 2001 2005 20,000 40,000 60,000 80,000 100,000 120,000 140,000
  5. 5. Impact of a Preventative AIDS Vaccine A 50% effective vaccine given to just 30% of the population could cut the 33 million projected number of new HIV infections in the developing world by more than half over 15 years. SOURCE: AIDS Vaccine Blueprint 2006, IAVI Report NOTE: Polio Vaccine is 60-70% effective / Flu Vaccine 70-90% effective O11_XTRA / NO VACCINE Vaccine Introduction 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 2010 2015 2020 2025 2030 30% Efficacy 20% Coverage 50% Efficacy 30% Coverage 70% Efficacy 40% Coverage Total New Infections Averted by an AIDS Vaccine between 2015 - 2030 5.5 Million 17 Million 28 Million
  6. 6. Total Annual Global Revenue* Projections for 1 st Generation AIDS Vaccines * Only Preventative Vaccine Revenue Reported; Therapeutic Market Estimated at $3.6B US/$3.6B ROW SOURCE: IAVI, October 2007 HIV/AIDS Preventative Vaccine Market O11_IRG / SCENARIO HIGH OPTIMISTIC BASELINE BASELINE LOW Peak Global Revenue $5.5B $4.8B $4.5B $2.5B Avg. Annual Sales Revenue (over years 0-30) $4.3B $3.2B $2.6B $1.4B Cumulative Sales Revenue over 30 year period $134.4B $98.4B $81.7B $43.8B 6 5 4 3 2 1 0 0 5 10 15 20 25 30 Years since FDA/EMEA regulatory approval
  7. 7. <ul><li>Preventative HIV/AIDS Vaccine </li></ul><ul><ul><li>Vaccine Used Before Infection </li></ul></ul><ul><ul><li>Proposed Universal Vaccine (Hepatitis, Polio, DPT) </li></ul></ul><ul><ul><li>Completing Phase 2a (Q4 2011) </li></ul></ul><ul><ul><li>Planning Phase 2b Efficacy Trial </li></ul></ul><ul><li>Therapeutic HIV/AIDS Vaccine </li></ul><ul><ul><li>Reduce Need for Drugs </li></ul></ul><ul><ul><li>Vaccine Used After Infection </li></ul></ul><ul><ul><li>Phase 1/2 Trial Enrolling </li></ul></ul><ul><li>Strong Government Support ($$) </li></ul><ul><ul><li>Research & Development </li></ul></ul><ul><ul><li>Clinical Trials </li></ul></ul><ul><li>IP Exclusively Licensed from Emory University </li></ul><ul><ul><li>6 issued / 5 pending US patents </li></ul></ul>GeoVax Company Overview O11_IRG /
  8. 8. <ul><li>Robert T. McNally, Ph.D., President & CEO </li></ul><ul><ul><li>Co-Founder: CryoLife, Inc. & Cell Dynamics, LLC </li></ul></ul><ul><li>Harriet L. Robinson, Ph.D., Chief Scientific Officer </li></ul><ul><ul><li>GeoVax Co-Founder, Emory University, University of Massachusetts </li></ul></ul><ul><li>Mark W. Reynolds, CPA, Chief Financial Officer </li></ul><ul><ul><li>CytRx Corporation, Arthur Andersen & Company </li></ul></ul><ul><li>Mark J. Newman, Ph.D., Vice President of R&D </li></ul><ul><ul><li>PaxVax, Inc., Pharmexa, Inc., Epimmune, Inc. </li></ul></ul>GeoVax Corporate Management O11_IRG /
  9. 9. <ul><li>David A. Dodd, Chairman </li></ul><ul><ul><li>VaxyGen, Serologicals, Solvay, Wyeth, BMS, Abbott </li></ul></ul><ul><li>Harriet L. Robinson, Ph.D., Chief Scientific Officer </li></ul><ul><ul><li>GeoVax Co-Founder and CSO, Emory University, University of Massachusetts </li></ul></ul><ul><li>Robert T. McNally, Ph.D., President & Chief Executive Officer </li></ul><ul><ul><li>GeoVax President/CEO, Co-Founder: CryoLife Inc. & Cell Dynamics LLC </li></ul></ul><ul><li>Steven S. Antebi </li></ul><ul><ul><li>Maple Capital Management, Galileo Partners, Bear Stearns </li></ul></ul><ul><li>Dean G. Kollintzas </li></ul><ul><ul><li>Intellectual Property Attorney </li></ul></ul><ul><li>Jack N. Spencer, Jr., CPA </li></ul><ul><ul><li>Ernst & Young </li></ul></ul>GeoVax Board of Directors O11_IRG /
  10. 10. COMPLETE PLANNED Product Portfolio O11_IRG / NOT REQUIRED
  11. 11. Preventative Vaccine
  12. 12. <ul><li>Designed to Vaccinate HIV Uninfected People </li></ul><ul><ul><li>Prevent Infection & Reduce Transmission </li></ul></ul><ul><ul><li>Potential Universal Vaccine with Global Need (Hepatitis B, Polio, DPT) </li></ul></ul><ul><li>Phase 2a Trial – Enrollment Completed </li></ul><ul><li>Phase 2b Efficacy Trial; GM-CSF Adjuvanted Vaccine (begin, 2013) </li></ul><ul><li>GM-CSF Adjuvanted Vaccine </li></ul><ul><li>Immune Stimulator in Provenge ® (Cancer Vaccine) </li></ul><ul><li>Enhances Prevention of Infection </li></ul><ul><li>Clinical Trials Accelerated Based on Outstanding Pre-Clinical Data </li></ul><ul><li>Expanded Government Support </li></ul>GeoVax Preventative AIDS Vaccine O11_IRG /
  13. 13. Phase 1 Human Trial – Government Supported Published by The Journal of Infectious Diseases Challenge Dose 30-300 Times Higher Than Typical Human Dose DNA Vaccine with GM-CSF Adjuvant (Primate Data) O11_IRG / 0 80 100 60 40 20 Number of Challenges 0 2 4 6 8 12 10 Percent Uninfected 70% Prevention of Infection 5 / 7 No Evidence of Infection – To Date >12 Months 100% Infection Controls (0 / 15 Protected)
  14. 14. Therapeutic Vaccine
  15. 15. <ul><li>Designed to Treat HIV Infected People </li></ul><ul><ul><li>Protect Individuals from Progressing to AIDS </li></ul></ul><ul><ul><li>Reduce Reliance on Oral Medication </li></ul></ul><ul><ul><li>Reduce Cost and Drug Related Side Effects </li></ul></ul><ul><li>Phase 1/2 Trial Enrolling </li></ul><ul><ul><li>Evaluating Safety </li></ul></ul><ul><ul><li>Collecting Immune Response Data </li></ul></ul><ul><ul><li>Evaluate Effect on Viral Load </li></ul></ul><ul><li>Compelling Pre-Clinical Results </li></ul>GeoVax Therapeutic Vaccine O11_IRG /
  16. 16. Unpublished Data: Dr. Rama Amara & Dr. Harriet Robinson 100x 1000x VACCINATION Pre-Clinical Therapeutic Trial Results O11_IRG / RJu9 Rlr9   0 12 50 58 66 72 112 10 7 10 5 10 3 Weeks Following Infection Infection Drug Treatment Started DNA DNA MVA Drug Treatment Interruption
  17. 17. GeoVax Vaccine Technology
  18. 18. <ul><li>Developed at Emory Vaccine Center, NIH, and CDC </li></ul><ul><li>Exclusively licensed from Emory University </li></ul><ul><li>5 issued and 6 pending patents related to AIDS vaccine components & compositions (2023) </li></ul><ul><li>29 issued or pending </li></ul><ul><li>patents in other countries </li></ul><ul><li>5 additional issued patents </li></ul><ul><li>related to AIDS vaccine </li></ul><ul><li>manufacturing process </li></ul>Strong Proprietary Technology Position O11_XTRA /
  19. 19. Rate of Vaccine Responses * Responding T cells, intracellular cytokine staining ** Anti-Env binding AB, ELISA *** After 6 intrarectal challenges with a dose 40-400 times higher than typical human dose NOTE: Polio Vaccine is 60-70% effective / Flu Vaccine 70-90% effective O11_XTRA /
  20. 20. Current Status: Therapeutic AIDS Vaccines O11_XTRA / Vaccine Sponsor Antibody (Ab to Env) T Cell Comments Bavarian Nordic MVA/BN Multiantigen NO YES Phase 1 Completed CD4 & CD8 T cells Bionor Immuno Vacc-4x Peptides NO YES Phase 2 Completed CD4 T cells but limited Response Rates Inovio PENNVAX™-B (pDNA) Unknown YES Phase 1 Active U Penn vaccine, CD4 & CD8 T cells Profectus BioSciences Multiantigen DNA + rVSV Unknown Unknown 2010 Start Planned ACTG Study GSK gp120+nef/tat fusion proteins & adjuvant YES YES Phase 1 Completed Low level neutralizing Ab, CD4 T cells Argos Therapeutics AGS-004 (RNA transfect DC) NO YES Phase 2b Active Personalized medicine approach GEOVAX DNA / MVA YES * YES * Phase 1 Enrolling * Data from GV Phase 1 trial in HIV Uninfected
  21. 21. Current Status: Preventative AIDS Vaccines Out of more than 80 vaccines entering HVTN Phase 1 testing, GeoVax Vaccines represent 2 of 6 to progress to Phase 2 O11_XTRA / Vaccine Sponsor Antibody (Ab to Env) T Cell Comments VaxGen gp 120 YES NO FAILED gp120, atypical Env Merck Ad5 NO YES FAILED Ad5 seropositive participants at higher risk NIH / VRC DNA Ad5 YES YES ENROLLING Limited to Ad5 seronegative, circumcised Not intended as commercial product Aventis ALVAC / gp120 YES LOW TRIAL COMPLETE Prevention of infection in 31% of Participants GEOVAX DNA / MVA YES YES PHASE 2a Enrollment Complete GEOVAX MVA / MVA YES YES PHASE 2a Addendum Enrollment Started December 2010
  22. 22. <ul><li>Leading Technology in Large Market Opportunity </li></ul><ul><li>Preventative and Therapeutic Applications </li></ul><ul><li>Over $50M in Non-Dilutive Government Support for Research Translation and Clinical Trials </li></ul><ul><li>Strong Intellectual Property Position </li></ul><ul><li>Significant Near-Term Clinical & Business Milestones </li></ul><ul><li>Compelling Valuation at Current Stock Price </li></ul><ul><li>Experienced Management Team with a Track Record of Success </li></ul>GeoVax -- Summary O11_IRG /
  23. 23. GeoVax Labs, Inc. Thank You!!

×